The goal is: 1) to develop new platinum drugs with increased tumor selectivity and increased cytocidal efficiency in combination with therapeutic radiation and 2) to study the biological interactions of platinum complexes with cellular components, especially DNA. A selected series of tetrachloroplatinum (II) nuclear staining (+)- charged molecule complexes will be prepared by the reaction of potassium tetrachloroplatinate with two molar equivalents of the dyes. Cytotoxicity, radiation sensitization and post-irrradiation effects of the platinum complexes will be studied under oxygenated and hypoxic conditions. Special attention will be given to potential lethal damage repair inhibition of x-irradiation, bleomycin and adriamycin. A murine and two human cell lines will be used for these experiments. In vivo studies will center on the efficacy of these agents in combination with radiation therapy. Drugs will be administered either 1 hr prior to or immediately following radiation treatment. The experiments will first be carried out at the maximum non-toxic dose of the drug and with single dose (10, 20 or 30 Gy) radiation treatment. The most promising agents will also be examined ina fractionated x-ray protocol with drug administered before or after each fraction. Antitumor activity of the complexes will be assessed in three murine tumors. To study drug penetration and to determine if these agents are producing true dose modification in combination with x-rays, tumor excision-cell survival assays will be performed. Density gradient separation of tumor subpopulations will be used to assess the effect of the treatment combinations on the hypoxic cell subpopulation of the tumor. Bone marrow survival will be determined by CFU-GM. Kidneys will be examined histologically. The binding of these complexes to DNA and the effects of these complexes on DNA repair in the presence and absence of x-rays will be assessed by two methods: 1) DNA alkaline elution of cells treated in vitro, and 2) digestion with T4 DNA polymerase (3' - 5') associated exonuclease of 5'-labelled, drug-treated DNA fragments of defined sequence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036508-05
Application #
3174129
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1984-01-01
Project End
1990-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Nguyen, T; Brownell, G L; Holden, S A et al. (1993) Subcellular distribution of various boron compounds and implications for their efficacy in boron neutron capture therapy by Monte Carlo simulations. Radiat Res 133:33-40
Nguyen, T; Brownell, G L; Holden, S A et al. (1993) Intracellular distribution of various boron compounds for use in boron neutron capture therapy. Biochem Pharmacol 45:147-55
Epelbaum, R; Teicher, B A; Holden, S A et al. (1992) Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo. Eur J Cancer 28A:794-800
Ara, G; Varshney, A; Ha, C S et al. (1992) Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light. Photochem Photobiol 55:561-7
Teicher, B A; Herman, T S; Holden, S A (1991) Effect of pH, oxygenation, and temperature on the cytotoxicity and radiosensitization by etanidazole. Int J Radiat Oncol Biol Phys 20:723-31
Herman, T S; Teicher, B A; Holden, S A (1991) Addition of mitomycin C to cis-diamminedichloroplatinum(II)/hyperthermia/radiation therapy in the FSaIIC fibrosarcoma. Int J Hyperthermia 7:893-903
Teicher, B A; Varshney, A; Khandekar, V et al. (1991) Effect of hypoxia and acidosis on the cytotoxicity of six metal(ligand)4(rhodamine-123)2 complexes at normal and hyperthermic temperatures. Int J Hyperthermia 7:857-68
Teicher, B A; Holden, S A; Herman, T S et al. (1991) Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 47:252-60
Teicher, B A; Pfeffer, M R; Alvarez Sotomayor, E et al. (1991) Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation. Int J Hyperthermia 7:773-84
Bubley, G J; Ashburner, B P; Teicher, B A (1991) Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells. Mol Carcinog 4:397-406

Showing the most recent 10 out of 32 publications